Business Context and Reporting Period
TradeUP Acquisition Corp. filed this Form 8-K on April 24, 2023, reporting an April 20, 2023 agreement with White Lion Capital, LLC. The transaction relates to TradeUP’s proposed business combination with Estrella Biopharma, Inc. The filing registrant is TradeUP Acquisition Corp., not Estrella Immunopharma, Inc.
Key Financial and Capital Markets Terms
- White Lion received the right, but not the obligation, to purchase up to $50 million of newly issued TradeUP common stock after completion of the business combination, subject to specified conditions and limitations.
- The purchase price will generally equal 97% of the lowest daily volume-weighted average price during a three-business-day valuation period. After White Lion purchases $25 million of stock, the discount changes to 2%, or 98% of the lowest daily VWAP.
- Individual purchases are subject to ownership, trading-volume and dollar-value limits, including a 4.99% beneficial ownership cap and limits generally tied to trading volume and a $1 million purchase amount.
- As consideration for White Lion’s commitment, Estrella is required, as soon as practicable after closing, to issue White Lion 250,000 shares of Estrella Series A preferred stock. The parties stated that these shares have a value of $250,000.
- TradeUP must register for resale the shares issuable under the purchase agreement and the shares issuable upon conversion of the Estrella preferred stock. The registration statement is to be filed within 30 days after consummation of the business combination, with customary damages provisions for filing or effectiveness delays.
- The filing provides no revenue, profit, cash flow, margin, debt or liquidity figures for TradeUP or Estrella.
Material Changes Versus the Prior Comparable Period
The filing does not present period-over-period operating or financial results. The material development is the entry into a potential $50 million equity financing facility and related registration rights agreement. No shares had been reported as purchased under the facility in this filing.
Guidance, Outlook, Risks and Unusual Items
- The facility is contingent on the business combination closing, the effectiveness of the registration statement and satisfaction of other conditions; White Lion is not obligated to purchase shares unless the applicable requirements are met.
- TradeUP may terminate the purchase agreement after the commencement date with three trading days’ notice, subject to delivery of the $250,000 commitment fee and consultation regarding related disclosures. White Lion also has termination rights for specified adverse events, trading suspensions, registration failures and company defaults.
- Potential equity issuance could dilute existing stockholders. The discount to VWAP and the absence of a guaranteed funding commitment may create additional financing and market risks.
- The proposed business combination remains subject to stockholder approvals and other closing conditions. The filing identifies risks involving limited operating history, transaction completion, available cash after redemptions, Nasdaq listing requirements, integration, market conditions and transaction costs.
- The filing contains forward-looking statements regarding the proposed transaction, post-transaction cash, enterprise value, growth and anticipated benefits, but provides no firm financial guidance.
Important Facts for Investors to Verify
- Whether the TradeUP-Estrella business combination closes and the date on which the financing facility becomes available.
- Whether the SEC declares the required resale registration statement effective within the specified period.
- Actual shares issued to White Lion, purchase prices, aggregate proceeds and resulting dilution.
- The terms governing conversion of the 250,000 Estrella Series A preferred shares.
- Cash available after stockholder redemptions, compliance with Nasdaq listing standards and any subsequent amendments or termination notices.
- The complete Common Stock Purchase Agreement and Registration Rights Agreement filed as Exhibits 10.1 and 10.2.